Get Ready, It’s Coming Next Week! What to Expect at COMPUTEX 2021
26.5.2021 10:36:00 EEST | Business Wire | Press release
COMPUTEX 2021 will be launched from May 31 to June 30. The organizer, the Taiwan External Trade Development Council (TAITRA), will roll out the #COMPUTEXVirtual platform to connect the technology community that breaks geographic limitations. COMPUTEX 2021 will offer an exceptional exhibition experience to attendees with the following highlights.
Highlight #1: Top Speakers Will Address on the Groundbreaking Technologies
COMPUTEX 2021 will kick off with the highly anticipated CEO Keynotes. From May 31 to June 2, key industry executives will discuss topics covering AI, high-performance computing (HPC), and other technology trends. Simon Segars, CEO of Arm, Dr. Lisa Su, President and CEO of AMD, Sanjay Mehrotra, President and CEO of Micron, Charles Liang, Founder, President and CEO of Supermicro, and Kurt Sievers, President and CEO of NXP Semiconductors are among the speaker lineup.
The COMPUTEX Forum on June 2 and 3 will revolve around the theme of "The New Era of Intelligence," focusing on key applications of AI, 5G, IoT, and electric vehicles. The forum will unlock the development of quantum computers and explore the infinite possibilities of future technology applications. The world's leading ICT experts will discuss business strategies and pulse industry trends in the post-pandemic era.
Highlight #2: Virtual Booths Will Showcase the Latest Products
#COMPUTEXVirtual, the all-new smart online platform, will use AI and automation technology to create an exceptional digital journey for users by providing a personalized interactive experience. Visitors will be able to obtain the latest product information in real-time.
Acer will showcase its very latest products and innovations that will be announced at its next@acer Global Press Conference to be held on May 27. It will also showcase solutions from its subsidiaries, including products for smart cities, AI, and enterprise use. ZOTAC, on the other hand, will be revealing a brilliant lineup of innovations, including the ZOTAC GAMING GeForce 3090 AMP Extreme Holo graphics card and the MAGNUS ONE ECM53060C mini PC.
Along with the big corporates, innovative startups are always the core elements to drive COMPUTEX and all the industry moving forward. The Epoch Foundation, committed to building partnerships in the global entrepreneurial community, has created a pavilion titled “Garage+ 46 Must-See Startups” on the #COMPUTEXVirtual platform. The exhibition is divided into three sections: “AI & Big Data,” “Digital Health & EdTech,” and “IoT & Energy.”
Moreover, #COMPUTEXVirtual builds #InnoVEXVirtual as a featured exhibit area to help startups connect with the international community. In addition to French Pavilion, Korean Pavilion, and the Dutch Pavilion, the European Bank for Reconstruction and Development (EBRD) is bringing 18 startups from 7 countries to join InnoVEX for the first time.
Highlight #3: Effective Online Platform Functions Will Synergize Matchmaking Opportunities
To maximize the benefits for exhibitors, #COMPUTEXVirtual will provide multiple effective, timely communication channels for exhibitors and visitors, such as video conferencing, meeting requests and instant messaging. Exhibitors can use AI technology to identify target audiences and promote products. Hyper-Personalized Recommendations will also help increase the matchmaking accuracy and enable companies to seize business opportunities effectively.
Together with the technology giants and disruptive startups, COMPUTEX 2021 is ready to bring the world an all-new digital experience. For more exhibition information, please visit the following:
- #COMPUTEXVirtual Online Exhibition Visitor Registration: https://virtual.computextaipei.com.tw/
- COMPUTEX CEO Keynote and COMPUTEX Forum Registration: https://virtual.computextaipei.com.tw/events/
About COMPUTEX TAIPEI (also called COMPUTEX):
Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.
About COMPUTEX 2021 Virtual:
As a pioneer in technology, COMPUTEX has been at the forefront in embracing digital transformation. In 2021, the show will go online. Together with the key global technology players, the organizer of COMPUTEX,Taiwan External Trade Development Council (TAITRA) introduces #COMPUTEXVirtual (including its global startups and innovations showcase #InnoVEXVirtual), an AI-driven virtual platform, and aims to deliver an exceptional virtual exhibition experience beyond the distance.
About TAITRA:
Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005459/en/
Contact information
For more updates：
COMPUTEX website: https://www.computextaipei.com.tw/
InnoVEX website : https://www.innovex.com.tw/
Press Contacts:
Ms. Tessa Lin <tessalin@taitra.org.tw
Ms. Li Chao < lichao@taitra.org.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom